Ñî¹óåú´«Ã½Ò•îl

The National Institute of Allergy and Infectious Diseases (NIAID) yesterday announced that it is enrolling participants for two phase 3 trials of two different monoclonal antibody treatments for COVID-19. The trials are enrolling healthy adults at risk for infection due to close contact at work or home, and the investigations are part of the COVID-19 Prevention Network recently established by NIAID, the group said in a news release. Anthony Fauci, MD, NIAID's director, said the network is designed to conduct large-scale trials rapidly and efficiently. (8/11)

In the present study, we attempt to quantify the potential impact of the spread of COVID-19 on Plasmodium falciparum malaria morbidity and mortality in Nigeria and across SSA using mathematical models of COVID-194 and malaria9. We assume that one disease does not directly influence the transmission or severity of the other, but that COVID-19 impacts malaria via the response to the epidemic and its repercussions on health systems. Predictions of the timing and magnitude of COVID-19 epidemics across African countries are highly uncertain and will vary according to how individual countries respond to COVID-19. (Sherrard-Smith et al, 8/7)

A majority of children were screened for ASD, but disparities exist among those screened. Benefits for screen-positive children are improved detection and younger age of diagnosis. Performance of the M-CHAT can be improved in real-world health care settings by administering screens with fidelity and facilitating timely ASD evaluations for screen-positive children. Providers should continue to monitor for signs of ASD in screen-negative children. (Carbone et al, 8/1)

PD-1 blockade is highly effective in classical Hodgkin lymphomas (cHLs), which exhibit frequent copy-number gains of CD274 (PD-L1) and PDC1LG2 (PD-L2) on chromosome 9p24.1. However, in this largely MHC-class-I-negative tumor, the mechanism of action of anti-PD-1 therapy remains undefined. We utilized the complementary approaches of T cell receptor (TCR) sequencing and cytometry by time-of-flight analysis to obtain a peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 phase II clinical trial (NCT02181738). (Zumla Cader et al, 8/10)

Experts in antibiotic resistance and sexually transmitted diseases (STDs) have long been worried about the growing resistance to the antibiotics used to treat gonorrhea. And with the emergence of multidrug-resistant strains of gonorrhea in recent years, those concerns have taken on a new urgency. (Dall, 8/10)